Search
Lipocine Inc
LPCNAdd to Watchlist
2.130USD
0.0000.00%
Close 08-07 16:00（ET）Quotes delayed by 15 min
15.92MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-07The current earnings forecast score of Lipocine Inc is 7.00, ranking 306 out of 387 in the Biotechnology & Medical Research industry. The average price target is 6.88, with a high of 7.00 and a low of 6.75.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+181.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Lipocine Inc
LPCN
2
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lipocine Inc's expected revenue for the next quarter?
Lipocine Inc's expected revenue is 159.50K.
What is Lipocine Inc's price target?
Analysts forecast that Lipocine Inc's price target is USD 6.88, with the highest forecast at USD 7.00 and the lowest forecast at USD 6.75.
How have Lipocine IncLPCN's recent earnings per share performed?
The market expectation was USD -0.32, while Lipocine IncLPCN's earnings per share (EPS) for the previous quarter was USD -0.54. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Lipocine Inc?
Based on the ratings of Lipocine Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.